TREM-1 and TREM-2 as therapeutic targets: clinical challenges and perspectives

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2024-12-16
DOI
https://doi.org/10.3389/fimmu.2024.1498993
Citations
4
Primary Topic
Inflammation biomarkers and pathways
Type
article
Field-Weighted Citation Impact
0.96

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TREM-1 and TREM-2 as therapeutic targets: clinical challenges and perspectives

Alexander B. Sigalov
4 citations
Frontiers in Immunology
Inflammation biomarkers and pathways
0.96
article

TREM-1 and TREM-2 as therapeutic targets: clinical challenges and perspectives

Alexander B. Sigalov
article en
4 citations

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 15
SignaBlok (United States) (US)
National Institutes of Health, National Heart, Lung, and Blood Institute, National Eye Institute, National Cancer Institute, National Institute of General Medical Sciences
Openalex Percentile: Top 24%
Inflammation biomarkers and pathways
0.96
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

TREM-1 and TREM-2 as therapeutic targets: clinical challenges and perspectives — Alexander B. Sigalov · Frontiers in Immunology (2024) | TGRS Research Map | TGRS